14-3-3η Amplifies Androgen Receptor Actions in Prostate Cancer

Purpose: Androgen receptor abundance and androgen receptor–regulated gene expression in castration-recurrent prostate cancer are indicative of androgen receptor activation in the absence of testicular androgen. Androgen receptor transactivation of target genes in castration-recurrent prostate cancer occurs in part through mitogen signaling that amplifies the actions of androgen receptor and its coregulators. Herein we report on the role of 14-3-3η in androgen receptor action. Experimental Design and Results: Androgen receptor and 14-3-3η colocalized in COS cell nuclei with and without androgen, and 14-3-3η promoted androgen receptor nuclear localization in the absence of androgen. 14-3-3η interacted with androgen receptor in cell-free binding and coimmunoprecipitation assays. In the recurrent human prostate cancer cell line, CWR-R1, native endogenous androgen receptor transcriptional activation was stimulated by 14-3-3η at low dihydrotestosterone concentrations and was increased by epidermal growth factor. Moreover, the dihydrotestosterone- and epidermal growth factor–dependent increase in androgen receptor transactivation was inhibited by a dominant negative 14-3-3η. In the CWR22 prostate cancer xenograft model, 14-3-3η expression was increased by androgen, suggesting a feed-forward mechanism that potentiates both 14-3-3η and androgen receptor actions. 14-3-3η mRNA and protein decreased following castration of tumor-bearing mice and increased in tumors of castrate mice after treatment with testosterone. CWR22 tumors that recurred 5 months after castration contained 14-3-3η levels similar to the androgen-stimulated tumors removed before castration. In a human prostate tissue microarray of clinical specimens, 14-3-3η localized with androgen receptor in nuclei, and the similar amounts expressed in castration-recurrent prostate cancer, androgen-stimulated prostate cancer, and benign prostatic hyperplasia were consistent with androgen receptor activation in recurrent prostate cancer. Conclusion: 14-3-3η enhances androgen- and mitogen-induced androgen receptor transcriptional activity in castration-recurrent prostate cancer. (Clin Cancer Res 2009;15(24):7571–81)

[1]  Yuhong Du,et al.  14‐3‐3 Proteins , 2009 .

[2]  M. Yaffe,et al.  Phosphoserine/Threonine Binding Domains , 2008 .

[3]  M. Sadar,et al.  14-3-3 sigma increases the transcriptional activity of the androgen receptor in the absence of androgens. , 2007, Cancer letters.

[4]  M. Yano,et al.  A novel function of 14-3-3 protein: 14-3-3zeta is a heat-shock-related molecular chaperone that dissolves thermal-aggregated proteins. , 2006, Molecular biology of the cell.

[5]  J. Nicolas,et al.  Receptor-interacting protein 140 is a repressor of the androgen receptor activity. , 2006, Molecular endocrinology.

[6]  M. Yaffe,et al.  Structural determinants of 14-3-3 binding specificities and regulation of subcellular localization of 14-3-3-ligand complexes: a comparison of the X-ray crystal structures of all human 14-3-3 isoforms. , 2006, Seminars in cancer biology.

[7]  A. Aitken.  14-3-3 proteins: a historic overview. , 2006, Seminars in cancer biology.

[8]  Haian Fu,et al.  Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. , 2006, Seminars in cancer biology.

[9]  H. Hermeking,et al.  14-3-3 proteins in cell cycle regulation. , 2006, Seminars in cancer biology.

[10]  B. E. Black,et al.  Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. , 2006, Molecular endocrinology.

[11]  J. Melamed,et al.  Cell-specific Regulation of Androgen Receptor Phosphorylation in Vivo* , 2005, Journal of Biological Chemistry.

[12]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  K. Tomer,et al.  Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer , 2005, Clinical Cancer Research.

[14]  M. Schell,et al.  Steroid 5α-Reductase Isozymes I and II in Recurrent Prostate Cancer , 2005, Clinical Cancer Research.

[15]  J. Mohler,et al.  Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. , 2005, Cancer research.

[16]  F. S. French,et al.  Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth , 2005, Clinical Cancer Research.

[17]  Bin He,et al.  Melanoma Antigen Gene Protein MAGE-11 Regulates Androgen Receptor Function by Modulating the Interdomain Interaction , 2005, Molecular and Cellular Biology.

[18]  J. Trapman,et al.  Phosphorylation of androgen receptor isoforms. , 2004, The Biochemical journal.

[19]  S. Plymate,et al.  Proteomic identification of 14-3-3 sigma as a common component of the androgen receptor and the epidermal growth factor receptor signaling pathways of the human prostate epithelial cell line M12 , 2004, Oncogene.

[20]  E. Wilson,et al.  An Androgen Receptor NH2-terminal Conserved Motif Interacts with the COOH Terminus of the Hsp70-interacting Protein (CHIP)* , 2004, Journal of Biological Chemistry.

[21]  Katie L Meehan,et al.  Quantitative profiling of LNCaP prostate cancer cells using isotope‐coded affinity tags and mass spectrometry , 2004, Proteomics.

[22]  F. S. French,et al.  Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer* , 2004, Journal of Biological Chemistry.

[23]  Desok Kim,et al.  The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.

[24]  H. Hermeking.  The 14-3-3 cancer connection , 2003, Nature Reviews Cancer.

[25]  V. Godfrey,et al.  CHIP activates HSF1 and confers protection against apoptosis and cellular stress , 2003, The EMBO journal.

[26]  E. Bissonette,et al.  Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. , 2003, Cancer research.

[27]  E. Wilson,et al.  Electrostatic Modulation in Steroid Receptor Recruitment of LXXLL and FXXLF Motifs , 2003, Molecular and Cellular Biology.

[28]  J T Arnold,et al.  Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. , 2002, Endocrine-related cancer.

[29]  J. Avruch,et al.  14-3-3 Proteins: Active Cofactors in Cellular Regulation by Serine/Threonine Phosphorylation* , 2002, The Journal of Biological Chemistry.

[30]  Desok Kim,et al.  Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. , 2002, The American journal of pathology.

[31]  D. Tindall,et al.  Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.

[32]  Spyro Mousses,et al.  Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling , 2001, Oncogene.

[33]  Jun Zhu,et al.  14-3-3 proteins; bringing new definitions to scaffolding , 2001, Oncogene.

[34]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[35]  F. S. French,et al.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.

[36]  J. Gustafsson,et al.  Regulation of glucocorticoid receptor activity by 14--3-3-dependent intracellular relocalization of the corepressor RIP140. , 2001, Molecular endocrinology.

[37]  M. Yaffe,et al.  Phosphoserine/threonine-binding domains. , 2001, Current opinion in cell biology.

[38]  F. S. French,et al.  Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. , 2001, Cancer research.

[39]  B. Haendler,et al.  Androgen receptor signalling: comparative analysis of androgen response elements and implication of heat-shock protein 90 and 14-3-3η , 2001, Molecular and Cellular Endocrinology.

[40]  Anthony J. Muslin,et al.  14-3-3 proteins: regulation of subcellular localization by molecular interference. , 2000, Cellular signalling.

[41]  F. S. French,et al.  Thyroid receptor activator molecule, TRAM-1, is an androgen receptor coactivator. , 2000, Endocrinology.

[42]  S. Rabindran,et al.  A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma. , 2000, The American journal of pathology.

[43]  Anthony J. Muslin,et al.  14‐3‐3 proteins block apoptosis and differentially regulate MAPK cascades , 2000, The EMBO journal.

[44]  S. Masters,et al.  14-3-3 proteins: structure, function, and regulation. , 2000, Annual review of pharmacology and toxicology.

[45]  H. Weiss,et al.  Androgenic regulation of growth factor and growth factor receptor expression in the cwr22 model of prostatic adenocarcinoma , 1999, International journal of cancer.

[46]  R. Lanz,et al.  Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.

[47]  S. Yeh,et al.  From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[48]  T. Pretlow,et al.  Changes in cyclin dependent kinase inhibitors p21 and p27 during the castration induced regression of the CWR22 model of prostatic adenocarcinoma. , 1999, The Journal of urology.

[49]  Desok Kim,et al.  Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. , 1998, Cancer research.

[50]  H. Klocker,et al.  Expression, structure, and function of androgen receptor in advanced prostatic carcinoma , 1998, The Prostate.

[51]  M. Stallcup,et al.  Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. , 1998, Molecular endocrinology.

[52]  R. Liddington,et al.  Raf-1 Kinase and Exoenzyme S Interact with 14-3-3ζ through a Common Site Involving Lysine 49* , 1997, The Journal of Biological Chemistry.

[53]  K. Hamil,et al.  Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. , 1997, Molecular endocrinology.

[54]  P. Gumerlock,et al.  Human androgen receptor expression in prostate cancer following androgen ablation. , 1997, European urology.

[55]  J. Isaacs,et al.  Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer , 1996, The Prostate.

[56]  J. Trapman,et al.  The androgen receptor in prostate cancer. , 1996, Pathology, research and practice.

[57]  H. Klocker,et al.  Distant metastases from prostatic carcinoma express androgen receptor protein. , 1995, Cancer research.

[58]  E. Wilson,et al.  Identification of three proline-directed phosphorylation sites in the human androgen receptor. , 1995, Molecular endocrinology.

[59]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[60]  S. Schwartz,et al.  CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. , 1994, Cancer research.

[61]  F. S. French,et al.  Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. , 1993, The Journal of urology.